BLTE BELITE BIO INC

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webcast on Monday, April 3, 2023, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the full year ended December 31, 2022, and provide a general business update. The financial results will be issued in a press release on Friday, March 31, 2023.

Webcast Information:

Date:Monday, April 3, 2023
Time:4:30 p.m. Eastern time (1:30 a.m. Pacific time)
Webcast Link:

Webcast Link Instructions

You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at . A replay will be available approximately two hours after the event for 90 days.

About Belite Bio

Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, such as advanced age-related macular degeneration (commonly known as Geographic Atrophy or advanced Dry AMD) and Stargardt disease, and metabolic diseases. For more information, follow us on , , , or visit us at .

Media and Investor Relations Contact:

Jennifer Wu /

Tim McCarthy



EN
31/03/2023

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of ...

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast subject visit completed in the pivotal Phase 3 DRAGON trial of Tinlarebant in Stargardt diseaseTopline data expected in Q4 2025 SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-sta...

September 12, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Up to $275 Million Upsized Private Placement Fina...

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with up to an additional $150 million tied to exercise of warrantsWarrants exercisable at a 20% premium to purchase price SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("Belite Bio" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advanci...

September 8, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in Three Upcoming Investor Conferences

Belite Bio to Participate in Three Upcoming Investor Conferences SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details of the presentations are as follows: Cantor Global Healthcare Conference September 5, 2025, at 8:00 am ET, fireside chat Morgan Stanley 23rd Annual Global Healthc...

August 27, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Reports Second Quarter 2025 Financial Results and Provides ...

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period)Enrollment completed with 529 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Raised approximately $15 million in gross proceeds in a registered direct offering on August 8, 2025Conference call and webcast on Monday, August 11, 2025, at 4:30 p.m. ET SAN DIEGO, Aug. 1...

August 11, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Registered Direct Offering of $15 Million

Belite Bio Announces Registered Direct Offering of $15 Million The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary Shares (“ADSs”) and warrants to purchase 230,770 ADSs, at a pur...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch